| Date | Title | Description |
| 08.08.2024 | Samsung Biologics Takes a Bold Step Towards Sustainable Supply Chains | In a world where sustainability is no longer a choice but a necessity, Samsung Biologics has made a significant move. The South Korean contract development and manufacturing organization (CDMO) has joined the Pharmaceutical Supply Chain Ini... |
| 06.08.2024 | Samsung Biologics joins the Pharmaceutical Supply Chain Initiative as Supplier Partner | Samsung Biologics to embed PSCI principles into business practices for responsible value chain management
Supplier Partnership reaffirms company's commitment to decarbonize and build resilient supply chains
INCHEON, South Korea, Aug. 6, 202... |
| 06.08.2024 | Samsung Biologics joins the Pharmaceutical Supply Chain Initiative as Supplier Partner | Samsung Biologics to embed PSCI principles into business practices for responsible value chain management
Supplier Partnership reaffirms company's commitment to decarbonize and build resilient supply chains
INCHEON, South Korea, Aug. 6, 202... |
| 01.07.2024 | South Korea June exports log ninth month of growth, misses forecasts | SEOUL : South Korea's exports increased for a ninth month in June, albeit at a slower pace than seen by analysts, as robust demand for chips continue to lead the export recovery in Asia's fourth-largest economy.
Overseas sales in June incre... |
| 29.05.2024 | Frost & Sullivan Reported The Fourth Revolutionary Wave of Biologics Manufacturing: CDMOs Empower Large-scale Production of Biologics | SHANGHAI, May 29, 2024 /PRNewswire/ -- Recently, Frost & Sullivan released the report "The Fourth Revolutionary Wave of Biologics Manufacturing: CDMOs Empower Large-scale Production of Biologics".
I. CDMOs are advancing the bi... |
| 24.05.2024 | Biocon signs licensing, supply deal for obesity drug in South Korea | - |
| 24.04.2024 | Samsung Biologics Reports First Quarter 2024 Financial Results | Recorded Q1'24 consolidated revenue of KRW 946.9 billion
Recorded Q1'24 consolidated operating profit of KRW 221.3 billion
Sustained growth driven by ongoing strategic expansion in capacity and portfolio
INCHEON, South Korea, April 24, 2024... |
| 04.03.2024 | Pharmaceutical Manufacturing Market Projected to Grow at 7.8% CAGR, Reaching $863.6 Bn by 2030 | Vantage Market Research | Vantage Market Research
Pharmaceutical Manufacturing Market Size, Share, Industry Trends, Growth, and Opportunities Analysis by 2030 WASHINGTON, D.C, DISTRICT OF COLUMBIA, UNITED STATES, March 4, 2024 /EINPresswire.com/ -- The Global Pharma... |
| 05.02.2024 | Samsung chief Jay Y. Lee acquitted in 2015 merger case | Samsung Electronics executive chairman Jay Y. Lee has been declared not guilty on the charge of stock price manipulation and accounting fraud related to the merger of Samsung affiliates in 2015, a South Korean Court ruled on Monday.
In the ... |
| 22.01.2024 | Cultivated meat in the spotlight at Tufts cellular ag day: ‘Focusing on science experiments that cannot scale is misleading people’ | Views about the current status of cultivated meat technology varied sharply at this year’s cellular ag innovation day at Tufts University, with industry skeptic Dr. Dave Humbird claiming it’s stuck at technology readiness level 3 and Ark Bi... |
| 26.07.2023 | Samsung Biologics Reports Second Quarter 2023 Financial Results | Recorded Q2'23 consolidated revenue of KRW 866.2 billion
Recorded Q2'23 consolidated operating profit of KRW 253.4 billion
Achieved record-high semi-annual revenue exceeding KRW 1,587.1 billion
Strong growth sustained with successful contra... |
| 18.07.2023 | Samsung Biologics releases 2023 ESG Report, reaffirming its commitment to net-zero progress and corporate social responsibility | INCHEON, South Korea, July 18, 2023 /PRNewswire/ -- Samsung Biologics (KRX: 207940), a global contract development and manufacturing organization (CDMO), today released its 2023 Environmental, Social and Governance (ESG) Report. The annual ... |
| 24.04.2023 | Samsung Biologics Reports First Quarter 2023 Financial Results | Recorded Q1'23 consolidated revenue of KRW 720.9 billion.
Recorded Q1'23 consolidated operating profit of KRW 191.7 billion.
Expected to maintain a strong growth trajectory with the full utilization of existing and newly expanded capacities... |
| 12.04.2023 | Samsung Ventures invests in Araris Biotech | |
| 17.03.2023 | Samsung Biologics announces construction of Plant 5 to commence Bio Campus II capacity expansion | The company plans to begin construction in the first half of 2023 and commence operations in 2025
As part of Samsung Biologics' second Bio Campus, Plant 5 will hold a manufacturing capacity of 180,000 liters, expanding the company's total s... |
| 27.01.2023 | Samsung Biologics Reports Fourth Quarter & Fiscal Year 2022 Financial Results | Q4'22 consolidated revenue of KRW 965.5 billion and Q4'22 operating profit of KRW 312.8 billion.
FY'22 consolidated revenue of KRW 3.00 trillion and FY'22 operating profit of KRW 983.6 billion.
Strong growth momentum expected to continue wi... |
| 11.01.2023 | Samsung Biologics receives the Terra Carta Seal in recognition of the company's commitment to creating a sustainable future | Samsung Biologics is one of 19 companies to have been awarded the 2022 Terra Carta Seal.
The Terra Carta Seal recognises global companies which are driving innovation and demonstrating their commitment to, and momentum towards, the creation... |
| 27.10.2022 | Samsung Biologics Reports Third Quarter 2022 Financial Results | Recorded consolidated revenue of KRW 873 billion in Q3'22
Recorded consolidated operating profit of KRW 324.7 billion in Q3'22
Started partial operations at Plant 4 within 23 months since groundbreaking as previously committed and launched ... |
| 14.10.2022 | Will the Taiwan Semiconductor Manufacturing Company of Drugs Be in East Asia? | On Aug. 25, President Biden signed the monumental $52.7 billion CHIPS and Science Act into law. The legislation is aimed to address the semiconductor manufacturing bottleneck in East Asia, namely the near-monopoly held on the industry by th... |
| 13.10.2022 | Samsung Biologics obtains three global ISO certifications | Receives accreditation for information security management system, information security in cloud services, and anti-bribery management systems
First global CDMO to be ISO 27001 and ISO 27017 certified
Earns Excellence Award for Integrated M... |
| 11.10.2022 | Samsung Biologics unlocks additional capacity for production at its newest Plant 4 | Plant 4 commences GMP operations within just 23 months since groundbreaking, as planned
Partial operations add fresh biomanufacturing capacity of 60,000 liters
Plant 4's total capacity of 240,000 liters to be ready early next year
INCHEON, ... |
| 29.09.2022 | Samsung Biologics introduces new development platforms S-DUAL™ and DEVELOPICK™ at BPI Boston 2022 | Two distinctive platforms will streamline the antibody development process.
With an advanced design and high binding affinity, S-DUAL™ ensures optimized manufacturability of bispecific antibodies.
DEVELOPICK™ provides early insight and sele... |
| 28.09.2022 | Samsung Biologics Earns Gold Rating from EcoVadis for Its Sustainability Efforts | Rising from last year's ranking, the company's united effort and dedication to integrating sustainable practices in all areas of its business drew recognition from EcoVadis, which provided high marks in responsible procurement and environme... |
| 01.08.2022 | GreenLight Biosciences and Samsung Biologics complete first commercial-scale engineering run for mRNA Covid-19 vaccine | GreenLight's messenger RNA production process is transferable to large-scale equipment and CMO facilities
Technology transfer and scale-up from lab bench to Samsung's commercial facility was completed in seven months
GreenLight's mRNA synth... |
| 27.07.2022 | Samsung Biologics Reports Second Quarter 2022 Financial Results | Released consolidated financial position of the company based on its full acquisition of Samsung Bioepis completed on April 20, 2022
Achieved record-high semi-annual revenue exceeding KRW 1 trillion
Recorded Q2'22 revenue of KRW 503.7 billi... |
| 18.07.2022 | Samsung Biologics to purchase land for its second Bio Campus | Acquires additional land, sized 357,366㎡ valued at KRW 426 billion, for Bio Campus 2
Plans to build Multi-Modal Plant, Open Innovation, and expanded manufacturing capacities
INCHEON, South Korea, July 18, 2022 /PRNewswire/ -- Samsung Biolog... |
| 11.07.2022 | ‘Sustainable CDMO’ Samsung Biologics releases 2022 ESG Report | Aims to build an eco-friendly business environment and achieve net zero GHG emissions in its operations, moving towards 100% renewable energy.
Details new social contribution activities that strives to support the health of its local commun... |
| 11.07.2022 | 'Sustainable CDMO' Samsung Biologics releases 2022 ESG Report | Aims to build an eco-friendly business environment and achieve net zero GHG emissions in its operations, moving towards 100% renewable energy.
Details new social contribution activities that strives to support the health of its local commun... |
| 27.04.2022 | Samsung Biologics Reports First Quarter 2022 Financial Results | Q1’22 revenue of KRW 511.3 billion increased 96% compared to Q1’21.
Q1’22 operating profit of KRW 176.4 billion increased 137% compared to Q1’21.
Stable business operations and utilization rates across Plants 1, 2, and 3.
Proactive investme... |
| 27.04.2022 | Samsung Biologics Reports First Quarter 2022 Financial Results | Q1'22 revenue of KRW 511.3 billion increased 96% compared to Q1'21.
Q1'22 operating profit of KRW 176.4 billion increased 137% compared to Q1'21.
Stable business operations and utilization rates across Plants 1, 2, and 3.
Proactive investme... |
| 20.04.2022 | Samsung Biologics completes full acquisition of Samsung Bioepis | Samsung Biologics has now fully acquired Samsung Bioepis, as a wholly owned subsidiary
First payment completed funded through paid-in capital
Accelerated growth expected in biosimilars and future novel therapeutics R&D
INCHEON, South Ko... |
| 29.03.2022 | Samsung Biologics holds 11th Annual General Meeting of Shareholders | INCHEON, South Korea, March 28, 2022 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), the world's leading contract development and manufacturing organization (CDMO), hosted its 11th Annual General Meeting of Shareholders (AGM) today. Fiv... |
| 07.02.2022 | Samsung Biologics receives 2022 CMO Leadership Award in all six categories | INCHEON, South Korea, Feb. 7, 2022 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), the world's leading contract development and manufacturing organization (CDMO), announced that it has been selected as a winner of the 2022 CMO Leadershi... |
| 28.01.2022 | Samsung Biologics reaches agreement with Biogen to acquire full ownership of Samsung Bioepis | Agreement with Biogen to buyout Biogen's (50% -1 share) stake in Samsung Bioepis Joint Venture for up to USD $2.3 billion
Transaction projected to be accretive to earnings in 2022 and thereafter, fully capitalizing on the high growth potent... |
| 28.01.2022 | Samsung выкупит долю Biogen в совместном производстве биоаналогов за $2,3 млрд | Samsung Biologics выкупит долю Biogen в размере 50% минус одна акция в их совместном предприятии Samsung Bioepis. Об этом сообщается на сайте Samsung Biologics. Сделка обойдется компании в $2,3 млрд.
Предполагается, что в права собственност... |
| 28.01.2022 | Samsung Biologics reaches agreement with Biogen to acquire full ownership of Samsung Bioepis | Agreement with Biogen to buyout Biogen's (50% -1 share) stake in Samsung Bioepis Joint Venture for up to USD $2.3 billion
Transaction projected to be accretive to earnings in 2022 and thereafter, fully capitalizing on the high growth potent... |
| 24.01.2022 | Samsung Biologics Reports Fourth Quarter & Fiscal Year 2021 Financial Results | Q4'21 revenue of KRW 444.3 billion increased 18% compared to Q4'20.
Q4'21 operating profit of KRW 128.8 billion increased 39% compared to Q4'20.
FY'21 revenue of KRW 1,568.0 billion, an increase of 35% compared to FY'20.
FY'21 operating pro... |
| 13.01.2022 | Samsung Biologics Shares Strategic Roadmap for Sustainable Growth at the 40th Annual JP Morgan Healthcare Conference | INCHEON, South Korea, Jan. 13, 2022 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS) announced its sustainable growth plan for this year at the 2022 Annual JP Morgan Healthcare Conference, which is held virtually from January 10th to 13th... |
| 14.12.2021 | Samsung Biologics and AstraZeneca expand strategic manufacturing partnership to include COVID-19 and cancer therapy | INCHEON, South Korea, Dec. 13, 2021 /PRNewswire/ -- Samsung Biologics (207940.KS), the world's leading contract development and manufacturing organization, continues its strategic biopharmaceutical manufacturing collaboration with AstraZene... |
| 14.12.2021 | Moderna COVID-19 Vaccine Manufactured in Korea by Samsung Biologics Receives Marketing Authorization from Ministry of Food and Drug Safety of Korea | CAMBRIDGE, Mass. and INCHEON, South Korea, Dec. 14, 2021 /PRNewswire/ -- Moderna (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announced today that the Ministry of Food and Drug Safety of... |
| 14.12.2021 | Moderna COVID-19 Vaccine Manufactured in Korea by Samsung Biologics Receives Marketing Authorization from Ministry of Food and Drug Safety of Korea | CAMBRIDGE, Mass. and INCHEON, South Korea, Dec. 14, 2021 /PRNewswire/ -- Moderna (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announced today that the Ministry of Food and Drug Safety of... |
| 07.12.2021 | Samsung Biologics adds to global ISO certifications with Quality Management System | Samsung Biologics earns ISO9001 for Quality Management System, proving its capabilities to ensure high-quality service offerings throughout a product life-cycle
The company is fully certified with the recognition across all of its CDO, CMO ... |
| 24.11.2021 | GreenLight Biosciences and Samsung Biologics announce collaboration to build capacity for messenger RNA Vaccine Manufacturing | BOSTON and INCHEON, South Korea, Nov. 24, 2021 /PRNewswire/ -- GreenLight Biosciences (Nasdaq: ENVI), a biotechnology company dedicated to making ribonucleic acid (RNA) products affordable and accessible for human health and agriculture, an... |
| 26.10.2021 | Samsung Biologics Reports Third Quarter 2021 Financial Results | Q3'21 revenue of KRW 450.7 billion increased 64% compared to Q3'20.
Q3'21 operating profit of KRW 167.4 billion increased 196% compared to Q3'20.
Stable supply, strong operational excellence and a high utilization rate across all plants.
Ac... |
| 22.09.2021 | Samsung Biologics showcases its newest CDO process platform, S-Cellerate™, at BPI 2021, offering expedited timeline to IND and BLA | INCHEON, South Korea, Sept. 22, 2021 /PRNewswire/ -- Samsung Biologics, a global contract development and manufacturing organization (CDMO), introduced its proprietary technology platform, S-CellerateTM, at the BioProcess International Conf... |
| 13.09.2021 | Samsung Biologics Joins Frontier 1.5D Project as part of 2050 Carbon Neutral Initiative | INCHEON, South Korea, Sept. 13, 2021 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), the world's leading contract development and manufacturing organization, announced the signing of an MOU today to participate in the Frontier 1.5D init... |
| 20.07.2021 | Kineta and Samsung Biologics Announce Development and Manufacturing Agreement for Anti-VISTA Antibody Immunotherapy | Kineta to leverage Samsung Biologics' development and manufacturing expertise to advance KVA12.1 to IND
Samsung Biologics San Francisco R&D center and South Korea headquarters to offer a seamless, end-to-end CDMO service
INCHEON, South ... |
| 25.06.2021 | Samsung Biologics Issues Its First Annual Sustainability Report | Consolidation of the company's roadmap to creating an improved business environment
Establishment of an ESG Committee for its continued efforts for environmental performance
Showcases the company's long-term commitment to social responsibil... |
| 23.06.2021 | Over a year into the global pandemic, Samsung Biologics continues to leverage innovative virtual platform for remote audits and regulatory inspections | Samsung Biologics' Live Virtual Tour (LVT) used in one of the earliest FDA full virtual assessments
Recently hosted EMA for 6 PAIs simultaneously using LVT
INCHEON, South Korea, June 23, 2021 /PRNewswire/ -- Samsung Biologics, a global cont... |
| 03.06.2021 | As the mRNA push continues, Samsung will expand its drug substance manufacturing at South Korean hub | As the demand for mRNA capacity grows, Samsung Biologics has announced the addition of drug substance production capability to its facilities by the first half of 2022, in an effort to ensure end-to-end mRNA vaccin... |
| 02.06.2021 | Samsung Biologics and KAHR Medical Announce Development and Manufacturing Agreement for Cancer Immunotherapy Drug Candidate | INCHEON, South Korea, June 2, 2021 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), the world's leading contract development and manufacturing organization, signed a strategic partnership with KAHR Medical Ltd., a cancer immunotherapy co... |
| 28.05.2021 | Samsung Biologics Adds Four Global ISO Certifications For BCMS, Energy, Health & Safety, and Environmental Management | Expanding upon its existing ISO22301 certification, Samsung Biologics is now fully certified with Business Continuity Management System for Security and Resilience across all business areas
Samsung Biologics adds ISO50001, ISO45001, ISO1400... |
| 23.05.2021 | Moderna and Samsung Biologics Announce Agreement for Fill-Finish Manufacturing of Moderna's COVID-19 Vaccine | CAMBRIDGE, Mass. and INCHEON, South Korea, May 23, 2021 /PRNewswire/ -- Moderna (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Samsung Biologics (KRX: 207940.KS), a leading global CDMO... |
| 25.04.2021 | Samsung Biologics and TG Therapeutics Expand Collaboration for the Large Scale Manufacture of Ublituximab | INCHEON, South Korea and NEW YORK, April 25, 2021 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), the world's leading contract development and manufacturing organization and TG Therapeutics (NASDAQ: TGTX), today announced an expansion o... |
| 16.12.2020 | Samsung Biologics promotes new CEO from within to head next phase of rapid manufacturing expansion | Riding a wave of red-hot investments in biologics, Samsung Biologics — the biopharma CDMO arm of the South Korean tech giant — is stringing together a series of major down payments on manufacturing. Now, the firm h... |
| 24.09.2020 | Samsung Biologics Reports Strong Q2 Result in Light of COVID-19 | Samsung Biologics is a fully integrated CDMO that offers one-stop services in development, manufacturing and biosafety testing. With the largest single-site capacity, Samsung Biologics is an award-winning company that has continued to opera... |
